Remtolumab (ABT-122) is a dual-variable domain immunoglobulin (DVD-IgTM
) that specifically neutralises both TNF alpha and interleukin-17A, which was investigated for clinical anti-rheumatic potential [1
]. We note that ABT-122 is no longer included on the developer's (AbbVie) pipeline web page, suggesting that development has ceased. No affinity data is readily available in peer reviewed literature and we have failed to identify peptide sequences for both the IL-17A and TNFα binding domains of the antibody in any single patent document that would allow definitive identification of ABT-122, despite AbbVie holding several patents describing IL-17A/TNFα binding immunoglobulins.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.